Clinical Trial Record

Return to Clinical Trials

Impact of Availability of Showerpatch for Patients With Intravenous Catheters


2016-01


2016-02


2016-03


18

Study Overview

Impact of Availability of Showerpatch for Patients With Intravenous Catheters

Venous catheters are necessary for the treatment of many patients. Showering with a venous catheter is often prohibited due to the infection risk when the insertion site becomes wet. Therefore these patients are challenged to keep the catheter insertion site dry and always covered with a dressing. Washing themselves is often impossible without assistance of a nurse or significant other. For patients with a catheter connected to an infusion line, it is even more difficult. Showerpatch is a newly developed dressing that safeguards the insertion site of an IV catheter from water during bathing activities. The purpose of this trial is to evaluate the impact of the availability of Showerpatch by comparing the outcomes in patients regarding the patient's autonomy in bathing activities, the material use and the time needed from caregivers in home care. Additionally qualitative data on patient's bathing activities and the use of Showerpatch will be collected.

N/A

  • Cystic Fibrosis
  • Pulmonary Hypertension
  • Neoplasms
  • DEVICE: Shower patch IV catheter protection
  • DEVICE: Conventional IV catheter protection
  • S57372
  • FC13145773 (OTHER_GRANT Identifier) (OTHER_GRANT: Flander's care)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2014-12-19  

N/A  

2016-03-29  

2014-12-19  

N/A  

2016-03-30  

2014-12-24  

N/A  

2016-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Supportive Care


Allocation:
Randomized


Interventional Model:
Crossover


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Shower patch IV catheter protection

Newly developed waterproof catheter dressing may be used for bathing activities

DEVICE: Shower patch IV catheter protection

  • Shower patch will be available for the patient for bathing activities
OTHER: Conventional IV catheter protection

No specific dressing will be provided to the patient to protect the catheter entry site during bathing activities.

DEVICE: Conventional IV catheter protection

  • No Shower patch will be provided during study period
Primary Outcome MeasuresMeasure DescriptionTime Frame
Self-reported autonomy score regarding bathing activitiesautonomy regarding bathing activities will be scored on a newly developed autonomy scale on a weekly basisWeekly until catheter removal which is expected on an average after 2 weeks or up to 8 weeks
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Number and type of bathing activitiesNumber and type of bathing activities per weekWeekly reported, until catheter removal which is expected on an average after 2 weeks or up to 8 weeks
Catheter dressing status: wetExpressed on a 3-point scale from 0 which means not wet to 2 totally wetBefore and after bathing activities, reported until catheter removal which is expected on an average after 2 weeks or up to 8 weeks
Catheter dressing status: looseExpressed on a 3-point scale from 0 which means not loose to 2 totally looseBefore and after bathing activities, reported until catheter removal which is expected on an average after 2 weeks or up to 8 weeks
Time needed from a caregiverTime expressed in minutes per weekWeekly reported, until catheter removal which is expected on an average after 2 weeks or up to 8 weeks
Material consumption regarding IV entry site care for bathing activitiesDescription of material which was used for catheter dressing protection and/or for the extra dressing change and/or extra securement of the dressing afterwards.Weekly reported, until catheter removal which is expected on an average after 2 weeks or up to 8 weeks
Clinical signs of local infectionRedness, tenderness, warmth, swelling or pus leakage recorded on a yes/no basisBefore and after bathing activities, reported until catheter removal which is expected on an average after 2 weeks or up to 8 weeks
Laboratory-Confirmed Bloodstream InfectionCollected at the end of the study by retrospective analysis of the patient file in case of hospital admissionUntil catheter removal which is expected on an average after 2 weeks or up to 8 weeks

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • able to read and speak Dutch and to fill out a web-based questionnaire
  • patients with an IV catheter (peripheral catheter, midline, peripherally inserted central catheter (PICC), Central Venous catheter (CVC), tunnelled catheter or implantable port) with an expected dwell time IV therapy of at least 14 days and with or without a prospect of discharge to the home setting with the IV catheter in situ in the foreseen study period
  • physically able to wash themselves
  • with access to the internet

  • Exclusion Criteria:

  • Bedridden patients
  • Patients who have already participated in an earlier stage of the ISIC study
  • Patients with more than one lumen of the catheter continuously connected to an infusion line

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • BEDAL
  • Remedus

  • PRINCIPAL_INVESTIGATOR: Godelieve A Goossens, PhD, Universitaire Ziekenhuizen KU Leuven

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S; Healthcare Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011 May;39(4 Suppl 1):S1-34. doi: 10.1016/j.ajic.2011.01.003. No abstract available.
  • Oakley C, Wright E, Ream E. The experiences of patients and nurses with a nurse-led peripherally inserted central venous catheter line service. Eur J Oncol Nurs. 2000 Dec;4(4):207-18. doi: 10.1054/ejon.2000.0099.
  • Molloy D, Smith LN, Aitchison T. Cytotoxic chemotherapy for incurable colorectal cancer: living with a PICC-line. J Clin Nurs. 2008 Sep;17(18):2398-407. doi: 10.1111/j.1365-2702.2008.02359.x.
  • Do AN, Ray BJ, Banerjee SN, Illian AF, Barnett BJ, Pham MH, Hendricks KA, Jarvis WR. Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. J Infect Dis. 1999 Feb;179(2):442-8. doi: 10.1086/314592.